Insights into pediatric rhabdomyosarcoma research: Challenges and goals

Marielle E. Yohe, Christine M. Heske, Elizabeth Stewart, Peter C. Adamson, Nabil Ahmed, Cristina R. Antonescu, Eleanor Chen, Natalie Collins, Alan Ehrlich, Rene L. Galindo, Berkley E. Gryder, Heidi Hahn, Sharon Hammond, Mark E. Hatley, Douglas S. Hawkins, Madeline N. Hayes, Andrea Hayes-Jordan, Lee J. Helman, Simone Hettmer, Myron S. IgnatiusCharles Keller, Javed Khan, David G. Kirsch, Corinne M. Linardic, Philip J. Lupo, Rossella Rota, Jack F. Shern, Janet Shipley, Sivasish Sindiri, Stephen J. Tapscott, Christopher R. Vakoc, Leonard H. Wexler, David M. Langenau

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.

Original languageEnglish (US)
Article numbere27869
JournalPediatric Blood and Cancer
Volume66
Issue number10
DOIs
StatePublished - Jan 1 2019

Fingerprint

Rhabdomyosarcoma
irinotecan
Pediatrics
Research
Vincristine
Survival Rate
Clinical Trials
Pharmaceutical Preparations
Therapeutics

Keywords

  • cancer biology
  • early-phase clinical trials
  • genomics
  • rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Yohe, M. E., Heske, C. M., Stewart, E., Adamson, P. C., Ahmed, N., Antonescu, C. R., ... Langenau, D. M. (2019). Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatric Blood and Cancer, 66(10), [e27869]. https://doi.org/10.1002/pbc.27869

Insights into pediatric rhabdomyosarcoma research : Challenges and goals. / Yohe, Marielle E.; Heske, Christine M.; Stewart, Elizabeth; Adamson, Peter C.; Ahmed, Nabil; Antonescu, Cristina R.; Chen, Eleanor; Collins, Natalie; Ehrlich, Alan; Galindo, Rene L.; Gryder, Berkley E.; Hahn, Heidi; Hammond, Sharon; Hatley, Mark E.; Hawkins, Douglas S.; Hayes, Madeline N.; Hayes-Jordan, Andrea; Helman, Lee J.; Hettmer, Simone; Ignatius, Myron S.; Keller, Charles; Khan, Javed; Kirsch, David G.; Linardic, Corinne M.; Lupo, Philip J.; Rota, Rossella; Shern, Jack F.; Shipley, Janet; Sindiri, Sivasish; Tapscott, Stephen J.; Vakoc, Christopher R.; Wexler, Leonard H.; Langenau, David M.

In: Pediatric Blood and Cancer, Vol. 66, No. 10, e27869, 01.01.2019.

Research output: Contribution to journalReview article

Yohe, ME, Heske, CM, Stewart, E, Adamson, PC, Ahmed, N, Antonescu, CR, Chen, E, Collins, N, Ehrlich, A, Galindo, RL, Gryder, BE, Hahn, H, Hammond, S, Hatley, ME, Hawkins, DS, Hayes, MN, Hayes-Jordan, A, Helman, LJ, Hettmer, S, Ignatius, MS, Keller, C, Khan, J, Kirsch, DG, Linardic, CM, Lupo, PJ, Rota, R, Shern, JF, Shipley, J, Sindiri, S, Tapscott, SJ, Vakoc, CR, Wexler, LH & Langenau, DM 2019, 'Insights into pediatric rhabdomyosarcoma research: Challenges and goals', Pediatric Blood and Cancer, vol. 66, no. 10, e27869. https://doi.org/10.1002/pbc.27869
Yohe ME, Heske CM, Stewart E, Adamson PC, Ahmed N, Antonescu CR et al. Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatric Blood and Cancer. 2019 Jan 1;66(10). e27869. https://doi.org/10.1002/pbc.27869
Yohe, Marielle E. ; Heske, Christine M. ; Stewart, Elizabeth ; Adamson, Peter C. ; Ahmed, Nabil ; Antonescu, Cristina R. ; Chen, Eleanor ; Collins, Natalie ; Ehrlich, Alan ; Galindo, Rene L. ; Gryder, Berkley E. ; Hahn, Heidi ; Hammond, Sharon ; Hatley, Mark E. ; Hawkins, Douglas S. ; Hayes, Madeline N. ; Hayes-Jordan, Andrea ; Helman, Lee J. ; Hettmer, Simone ; Ignatius, Myron S. ; Keller, Charles ; Khan, Javed ; Kirsch, David G. ; Linardic, Corinne M. ; Lupo, Philip J. ; Rota, Rossella ; Shern, Jack F. ; Shipley, Janet ; Sindiri, Sivasish ; Tapscott, Stephen J. ; Vakoc, Christopher R. ; Wexler, Leonard H. ; Langenau, David M. / Insights into pediatric rhabdomyosarcoma research : Challenges and goals. In: Pediatric Blood and Cancer. 2019 ; Vol. 66, No. 10.
@article{3758f8e391ff45fc99d9b24235221a65,
title = "Insights into pediatric rhabdomyosarcoma research: Challenges and goals",
abstract = "Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.",
keywords = "cancer biology, early-phase clinical trials, genomics, rhabdomyosarcoma",
author = "Yohe, {Marielle E.} and Heske, {Christine M.} and Elizabeth Stewart and Adamson, {Peter C.} and Nabil Ahmed and Antonescu, {Cristina R.} and Eleanor Chen and Natalie Collins and Alan Ehrlich and Galindo, {Rene L.} and Gryder, {Berkley E.} and Heidi Hahn and Sharon Hammond and Hatley, {Mark E.} and Hawkins, {Douglas S.} and Hayes, {Madeline N.} and Andrea Hayes-Jordan and Helman, {Lee J.} and Simone Hettmer and Ignatius, {Myron S.} and Charles Keller and Javed Khan and Kirsch, {David G.} and Linardic, {Corinne M.} and Lupo, {Philip J.} and Rossella Rota and Shern, {Jack F.} and Janet Shipley and Sivasish Sindiri and Tapscott, {Stephen J.} and Vakoc, {Christopher R.} and Wexler, {Leonard H.} and Langenau, {David M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/pbc.27869",
language = "English (US)",
volume = "66",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Insights into pediatric rhabdomyosarcoma research

T2 - Challenges and goals

AU - Yohe, Marielle E.

AU - Heske, Christine M.

AU - Stewart, Elizabeth

AU - Adamson, Peter C.

AU - Ahmed, Nabil

AU - Antonescu, Cristina R.

AU - Chen, Eleanor

AU - Collins, Natalie

AU - Ehrlich, Alan

AU - Galindo, Rene L.

AU - Gryder, Berkley E.

AU - Hahn, Heidi

AU - Hammond, Sharon

AU - Hatley, Mark E.

AU - Hawkins, Douglas S.

AU - Hayes, Madeline N.

AU - Hayes-Jordan, Andrea

AU - Helman, Lee J.

AU - Hettmer, Simone

AU - Ignatius, Myron S.

AU - Keller, Charles

AU - Khan, Javed

AU - Kirsch, David G.

AU - Linardic, Corinne M.

AU - Lupo, Philip J.

AU - Rota, Rossella

AU - Shern, Jack F.

AU - Shipley, Janet

AU - Sindiri, Sivasish

AU - Tapscott, Stephen J.

AU - Vakoc, Christopher R.

AU - Wexler, Leonard H.

AU - Langenau, David M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.

AB - Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.

KW - cancer biology

KW - early-phase clinical trials

KW - genomics

KW - rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85067837593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067837593&partnerID=8YFLogxK

U2 - 10.1002/pbc.27869

DO - 10.1002/pbc.27869

M3 - Review article

C2 - 31222885

AN - SCOPUS:85067837593

VL - 66

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 10

M1 - e27869

ER -